https://sputnikglobe.com/20210309/eu-regulator-to-make-decisions-on-sputnik-v-vaccine-based-only-on-scientific-data-1082294439.html
EU Regulator to Make Decisions on Sputnik V Vaccine Based Only On Scientific Data
EU Regulator to Make Decisions on Sputnik V Vaccine Based Only On Scientific Data
Sputnik International
BRUSSELS (Sputnik) - The European Medicines Agency (EMA) will review the compliance of Sputnik V, a Russian vaccine against COVID-19, with standards of the... 09.03.2021, Sputnik International
2021-03-09T15:15+0000
2021-03-09T15:15+0000
2023-04-12T17:13+0000
https://cdn1.img.sputnikglobe.com/img/07e5/03/01/1082223356_0:67:3119:1830_1920x0_80_0_0_f925c918f02e3487765c5db2a513332e.jpg
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
https://cdn1.img.sputnikglobe.com/img/07e5/03/01/1082223356_0:0:3119:1962_1920x0_80_0_0_3e113615aa7bee9ff1b3d93cd6080015.jpgSputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
europe, newsfeed, vaccine, coronavirus, european union (eu)
europe, newsfeed, vaccine, coronavirus, european union (eu)
EU Regulator to Make Decisions on Sputnik V Vaccine Based Only On Scientific Data
15:15 GMT 09.03.2021 (Updated: 17:13 GMT 12.04.2023) BRUSSELS (Sputnik) - The European Medicines Agency (EMA) will review the compliance of Sputnik V, a Russian vaccine against COVID-19, with standards of the European Union and make recommendations based solely on the scientific data, a spokesperson from the EMA told Sputnik on Tuesday.
According to the spokesperson, the EMA is currently evaluating Sputnik V via a rolling review procedure. The representative added that the EU drug regulator will make its recommendations on Sputnik V based solely on scientific data on the effectiveness and safety of the Russian vaccine and nothing else.
The EMA spokesperson also said that the regulator will review data on Sputnik V as it becomes available to decide if the benefits of the vaccine outweigh its risks.
In August 2020, Russia became the first country in the world to register a vaccine against the coronavirus, dubbed Sputnik V, and developed by the Gamaleya research institute.
According to analysis of phase 3 clinical trials of Sputnik V, published by The Lancet medical journal, Sputnik V has 91.6 percent efficacy against symptomatic COVID-19.
On Thursday, EMA announced that it had started a rolling review to test the Russian vaccine for compliance with EU standards for effectiveness, safety and quality.